<DOC>
	<DOCNO>NCT00403429</DOCNO>
	<brief_summary>The purpose study evaluate activity toxicity capecitabine monotherapy treatment platinum resistant refractory ovarian cancer .</brief_summary>
	<brief_title>MITO-6 : Capecitabine Platinum Resistant Ovarian Cancer</brief_title>
	<detailed_description>Ovarian cancer second frequent deadly gynaecologic cancer . Standard combination chemotherapy platinum derivative ( cisplatin carboplatin ) taxane effective cause remission 60 - 80 % case , yet recurrences frequent 5-year survival 20 % . Current therapy second line treatment recurrence patient platinum refractory ( experienced progression disease first line platinum base therapy ) platinum resistant ( experienced recurrence disease within 6 month complete platinum base therapy ) ovarian cancer limit . Capecitabine , oral chemotherapy already use colon breast cancer , show promise early clinical trial treat recurrent ovarian cancer . Patients enter trial receive oral capecitabine 1250 mg/m2 day 1-14 every 21 day 6 cycle , depend response .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Cytologic histologic diagnosis relapse ovarian cancer Refractory resistant platinum salt disease Age &lt; 75 year At least one measurable lesion ( ³ 20 mm conventional technique ³ 10 mm spiral CT scan ) Life expectancy least 3 month Written inform consent Previous concomitant malignant neoplasia within 5 year prior basal evaluation ( exclude adequately treat basocellular spinocellular skin carcinoma situ carcinoma uterine cervix ) . Performance Status ( ECOG ) ³ 3 Previous chemotherapy treatment capecitabine More 3 line chemotherapy Heart disease ( heart failure , heart attack 6 month prior trial , atrioventricular block degree , serious arrhythmia ) Leukocytes &lt; 4000/mm3 , platelet &lt; 100000/mm3 Modifications renal function ( Creatinine ³ 1.25 time upper normal limit ) liver function ( SGOT SGPT ³ 1.25 time upper normal limit ) Present suspect haemorrhagic syndrome Uncooperative and/or unreliable patient Patients ' inability access centre</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>oral chemotherapy</keyword>
	<keyword>platinum resistant</keyword>
	<keyword>platinum refractory</keyword>
	<keyword>second line</keyword>
</DOC>